Tag: Siliq

According to population pharmacokinetic modeling, the effective half-life of Siliq (brodalumab) at steady state is approximately 10.9 to 11.7 days. Understanding what is the half-life of Siliq is crucial for determining its dosing schedule and overall therapeutic efficacy in treating moderate to severe plaque psoriasis.

Plaque psoriasis affects an estimated 3% of adults in the United States, which translates to over 7.5 million people [1.9.1, 1.9.2]. For those exploring treatment options, understanding what is similar to Bimzelx is a crucial step in managing this chronic condition.

Originally developed by Amgen, the biologic medication brodalumab underwent several key ownership changes before its market debut, creating a complex manufacturing and commercialization landscape. The answer to who makes brodalumab depends heavily on the geographic region, as different pharmaceutical companies hold marketing rights in different parts of the world.